{
    "ticker": "ASTH",
    "name": "Asterias Biotherapeutics, Inc.",
    "description": "Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative cell-based therapies for the treatment of cancer and degenerative diseases. Founded in 2013, Asterias aims to harness the power of regenerative medicine to improve patient outcomes and quality of life. The company's lead product candidate, AST-OPC1, is a novel treatment for spinal cord injuries, utilizing oligodendrocyte precursor cells derived from human embryonic stem cells. This therapy is designed to promote neural repair and enhance recovery in patients with significant neurological deficits. Asterias is also exploring the potential of its technology platform for applications in various other disease areas, including oncology and autoimmune disorders. With a strong commitment to scientific excellence and innovation, Asterias collaborates with leading academic institutions and research organizations to advance its therapeutic candidates through clinical trials. The company is dedicated to addressing unmet medical needs and contributing to the evolving landscape of regenerative medicine, aiming to bring transformative therapies to patients in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2013",
    "website": "https://www.asteriasbiotherapeutics.com",
    "ceo": "Richard Garr",
    "social_media": {
        "twitter": "https://twitter.com/asteriasbio",
        "linkedin": "https://www.linkedin.com/company/asterias-biotherapeutics"
    },
    "investor_relations": "https://www.asteriasbiotherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Richard Garr",
            "position": "CEO"
        },
        {
            "name": "Dr. John D. E. O'Leary",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "AST-OPC1"
            ]
        }
    ],
    "seo": {
        "meta_title": "Asterias Biotherapeutics, Inc. | Innovative Cell-Based Therapies",
        "meta_description": "Explore Asterias Biotherapeutics, Inc., a leader in regenerative medicine focused on developing innovative cell-based therapies for treating cancer and spinal cord injuries.",
        "keywords": [
            "Asterias Biotherapeutics",
            "Regenerative Medicine",
            "Cell Therapies",
            "AST-OPC1",
            "Biotechnology",
            "Spinal Cord Injury Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Asterias Biotherapeutics known for?",
            "answer": "Asterias Biotherapeutics is known for developing cell-based therapies, particularly for spinal cord injuries."
        },
        {
            "question": "Who is the CEO of Asterias Biotherapeutics?",
            "answer": "Richard Garr is the CEO of Asterias Biotherapeutics, Inc."
        },
        {
            "question": "Where is Asterias Biotherapeutics headquartered?",
            "answer": "Asterias Biotherapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Asterias' lead product candidate?",
            "answer": "Asterias' lead product candidate is AST-OPC1, a treatment for spinal cord injuries."
        },
        {
            "question": "When was Asterias Biotherapeutics founded?",
            "answer": "Asterias Biotherapeutics was founded in 2013."
        }
    ],
    "competitors": [
        "REGN",
        "CRIS",
        "ADMS"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "VRTX"
    ]
}